Trial · NCT05096728
Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)
NCT05096728, Completed, Ohio State University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI). Trials, record NCT05096728. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05096728
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)
- NCT number
- NCT05096728
- Status
- Completed
- Enrollment
- 56 participants, actual
- Lead sponsor
- Ohio State University
- Conditions
- Preeclampsia With Severe Features
- Interventions
- Nifedipine XL
- First posted
- 2021-10-27
- Last updated
- 2023-12-22
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Comparing the rates of suboptimal blood pressure | on day 2 (24 hour-48 hour) after the patient has been enrolled | Comparing the rates of suboptimal blood pressure, defined as frequency of systolic \>150 mmHg and/or diastolic \>100 mmHg blood pressure. Blood pressure measurements will be measured every 4 hours on day 2 (24 hour-48 hour) after the patient has been enrolled, randomized, and initiated on either once daily Nifedipine XL 60mg or twice daily Nifedipine XL 30mg. |
| Secondary | Evaluating mean systolic and diastolic blood pressure and mean arterial pressure | on day 2 (24 hour-48 hour) after the patient has been enrolled | Evaluating mean systolic and diastolic blood pressure and mean arterial pressure measured on day 2 (24h-48h) after the patient has been enrolled, randomized, and initiated on Nifedipine regimen |
| Secondary | Evaluating concentration of Nifedipine in blood | on day 2 (24 hour-48 hour) after the patient has been enrolled | Evaluating concentration of Nifedipine in blood measured at prespecified times taken on day 2 (24 hour-48 hour) after the patient has been enrolled, randomized, and initiated on a Nifedipine regimen |
| Secondary | Evaluating number of route of delivery | Through study completion, an average of 2 years | |
| Secondary | Evaluating number of days in expectant management from enrollment | Through study completion, an average of 2 years | |
| Secondary | Evaluating frequency of indications for cesarean section | Through study completion, an average of 2 years | |
| Secondary | Evaluating frequency of need for acute acting anti-hypertensive treatment (IR Nifedipine, IV labetalol, or IV hydralazine) | on day 2 (24 hour-48 hour) after the patient has been enrolled | |
| Secondary | Evaluating number of delivery less than 34 weeks | Through study completion, an average of 2 years | |
| Secondary | Evaluating gestational age at delivery | Through study completion, an average of 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05096728
GET https://conductscience.org/api/trials/v1/NCT05096728/registered